ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1268

Evaluating Numeric Rating Scale Versions of the 3 and 4 Visual Analog Scale (3/4-VAS) Composite Measures in Patients with Active Psoriatic Arthritis from the SELECT-PsA Program
Abstract Number: 1269

Implementing RAPID-3 Using Electronic Patient Portal and Point of Care Entry
Abstract Number: 1270

MDHAQ/RAPID3 Is a Feasible Tool to Estimate High Comorbid Fatigue and Residual Fatigue in Rheumatoid Arthritis Patients
Abstract Number: 1271

Uptake of Rheumatology-Specific Quality Measures Submitted to National Pay-for-Performance Programs: An Analysis of Participants in the RISE Registry
Abstract Number: 1272

Application of the Consolidated Framework for Implementation Research (CFIR) to Study Top-Performing Practices in the RISE Registry
Abstract Number: 1273

Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: Data Availability and Preliminary Measure Performance in the RISE Registry
Abstract Number: 1274

Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
Abstract Number: 1275

Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic
Abstract Number: 1276

Bone Density Imaging: Evaluation of Equipment and Process of Care Quality in US Veterans
Abstract Number: 1277

Improving Patient Appropriate Osteoporosis Screening with Dual Energy X-ray Absorptiometry Scans in an Academic Internal Medicine Practice
Abstract Number: 1278

ANA Testing Practices in the United States: A Population-Based Study Between 2000 and 2019
Abstract Number: 1279

Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: A Literature Review and Modified Delphi Consensus Study
Abstract Number: 1280

Patients with Systemic Lupus Erythematosus Perceive the Quality of Care They Receive to Be Suboptimal
Abstract Number: 1281

Less Than Half of Cryoglobulin Tests Ordered at a Tertiary Hospital Network Are Successfully Completed: An Opportunity for Improvement
Abstract Number: 1282

Practice Patterns for Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Among Nephrologists and Rheumatologists – an International Survey Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].